Skip to search formSkip to main contentSkip to account menu

doranidazole

Known as: (2RSs,3SR)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Imidazoles

Narrower (1)

PR 350

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Preclinical study on hypoxic radiosensitizing effects of glycididazole in comparison with those of doranidazole in vitro and in vivo.
To overcome the radioresistance of hypoxic cells in solid tumor, numerous types of radiosensitizers specifically against them… 
2013
2013
The prospective application of a hypoxic radiosensitizer, doranidazole to rat intracranial glioblastoma with blood brain barrier disruption
BackgroundGlioblastoma is one of the intractable cancers and is highly resistant to ionizing radiation. This radioresistance is… 
2006
2006
Phase I/II trial of doranidazole (PR-350) and concurrent thoracic radiotherapy (TRT) in patients (pts) with locally advanced (LA) non-small cell lung cancer (NSCLC).
17064 Background: PR-350 was a nitoroimidazole derivative as a hypoxic cell radiosensitizer with low toxixity, developed by POLA… 
2005
2005
Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
We have investigated the radiosensitizing effect of doranidazole, a hypoxic cells radiosensitizer, using SCCVII tumor cells of… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials reported in current literature and congresses. The data… 
2004
2004
Doranidazole in the radiosensitization of hypoxic pancreatic cancer cells
Objective To investigate the effects of a new radiosensitizer, nitroimidazole-derivative--Doranidazole on pancreatic cancer cells… 
2002
2002
Effect of a hypoxic cell sensitizer doranidazole on the radiation-induced apoptosis of mouse L5178Y lymphoma cells.
We investigated the sensitizing effect of the 2-nitroimidazole analogue doranidazole, a new hypoxic radiosensitizer, on radiation… 
2002
2002
Radiation-chemical properties of the hypoxic cell radiosensitizer doranidazole (PR-350).
This study was performed to confirm the radiation-chemical properties of the 2-nitroimidazole derivative doranidazole, (+/-)-(2RS… 
2001
2001
Phase Ia study of a hypoxic cell sensitizer doranidazole (PR-350) in combination with conventional radiotherapy
A phase Ia study of a 2-nitroimidazole nucleoside analog radiosensitizer doranidazole was conducted to evaluate its toxicity and… 
2000
2000
Radiosensitivity of human pancreatic cancer cells in vitro and in vivo, and the effect of a new hypoxic cell sensitizer, doranidazole.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)